Rani Therapeutics Holdings, Inc.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
RANI$0.57+5.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity
| Class A Common Stock · Class B Common Stock | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Additional Paid In Capital | Accumulated Other Comprehensive Loss | Accumulated Deficit | Non-Controlling Interest | Total Stockholders' Equity | |
| Balance at December 31, 2022 | 25,295 | $3 | 24,116 | $2 | $75,842 | $(73) | $(38,919) | $37,149 | $74,004 |
| Issuance of common stock under employee equity plans, net of shares withheld for tax settlement | 557 | — | — | — | (162) | — | — | — | (162) |
| Issuance of common stock under employee stock purchase plan | 144 | — | — | — | 355 | — | — | — | 355 |
| Effect of exchanges of Paired Interests and non-corresponding Class A Units of Rani LLC | 42 | — | — | — | — | — | — | — | — |
| Non-controlling interest adjustment for changes in proportionate ownership in Rani LLC | — | — | — | — | 181 | — | — | (181) | — |
| Forfeiture of restricted stock awards | (2) | — | — | — | (6) | — | — | (6) | (12) |
| Stock-based compensation | — | — | — | — | 9,552 | — | — | 9,468 | 19,020 |
| Net loss | — | — | — | — | — | — | (33,970) | (33,913) | (67,883) |
| Other comprehensive gain | — | — | — | — | — | 61 | — | 60 | 121 |
| Balance at December 31, 2023 | 26,036 | $3 | 24,116 | $2 | $85,762 | $(12) | $(72,889) | $12,577 | $25,443 |
| Issuance of common stock in connection with the October Securities Purchase Agreement, net of issuance costs of $621 | 3,000 | — | — | — | 9,379 | — | — | — | 9,379 |
| Exercise of pre-funded warrants issued in connection with the October Securities Purchase Agreement | 333 | — | — | — | — | — | — | — | — |
| Issuance of common stock in connection with the July Securities Purchase Agreement, net of issuance costs of $1,117 | 2,800 | — | — | — | 8,883 | — | — | — | 8,883 |
| Exercise of pre-funded warrants issued in connection with the July Securities Purchase Agreement | 447 | — | — | — | — | — | — | — | — |
| Issuance of common stock under employee equity plans, net of shares withheld for tax settlement | 395 | — | — | — | 4 | — | — | — | 4 |
| Issuance of common stock under employee stock purchase plan | 159 | — | — | — | 304 | — | — | — | 304 |
| Effect of exchanges of Paired Interests and non-corresponding Class A Units of Rani LLC | 260 | — | (144) | — | — | — | — | — | — |
| Non-controlling interest adjustment for changes in proportionate ownership in Rani LLC | — | — | — | — | (7,980) | — | — | 7,980 | — |
| Stock-based compensation | — | — | — | — | 8,537 | — | — | 7,494 | 16,031 |
| Net loss | — | — | — | — | — | — | (30,018) | (26,566) | (56,584) |
| Other comprehensive gain | — | — | — | — | — | 17 | — | 16 | 33 |
| Balance at December 31, 2024 | 33,430 | $3 | 23,972 | $2 | $104,889 | $5 | $(102,907) | $1,501 | $3,493 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.